Passage Bio


Clinical-stage genetic medicines company developing adeno-associated virus (AAV)-based gene therapies for neurodegenerative diseases of the central nervous system. Programs include AAV vector engineering, preclinical evaluation in animal models, scalable AAV manufacturing process development, and multinational early-phase clinical trials with cerebrospinal fluid delivery and biomarker-based assessments. The company publishes preclinical and clinical data and maintains public financial and regulatory filings.

Industries

Biotechnology
Health Care
Therapeutics
Wellness
Pharmaceutical and biotechnology
Biotechnology Research

Nr. of Employees

medium (51-250)

Passage Bio

Philadelphia, Pennsylvania, United States


Products

AAV-based GRN gene therapy candidate (investigational)

An investigational AAV-based gene therapy designed to deliver a functional GRN transgene to the central nervous system via a single intra-cisterna magna administration to increase progranulin levels in genetic neurodegenerative disease.

Multinational Phase 1/2 clinical study of GRN-directed CNS gene therapy

Early-phase clinical study evaluating safety, tolerability and biomarker outcomes of an investigational GRN-directed gene therapy in participants with genetic frontotemporal dementia.


Services

No-cost genetic testing and counseling programs for patients suspected of having genetic neurodegenerative disease, delivered via third-party testing and counseling providers to support patient identification and trial enrollment.

Expertise Areas

  • Gene therapy development
  • AAV vector engineering and cassette design
  • Intrathecal/cerebrospinal fluid delivery for CNS indications
  • Early-phase (Phase 1/2) clinical trial management
  • Show More (6)

Key Technologies

  • Adeno-associated virus (AAV) vectors and serotype selection
  • Recombinant AAV expression cassette construction
  • Intrathecal / intra-cisterna magna cerebrospinal fluid delivery
  • Image-guided delivery techniques for CNS administration
  • Show More (4)

News & Updates

Webcast and presentation discussing the proposed merger agreement between the company and Remix Therapeutics.

Conference poster presenting interim safety and biomarker data from a Phase 1/2 trial of an AAV gene therapy candidate for frontotemporal dementia caused by GRN mutations.

Poster presentation related to clinical program biomarker and clinical data summaries.

Poster describing process transition and scale-up from adherent cell culture to suspension-based triple transfection for AAV manufacturing.

Conference presentation covering program updates and scientific data related to CNS gene therapy development.

Conference presentation summarizing nonclinical and early clinical development data for a GRN-targeted AAV gene therapy.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.